Asset profile
Mebufotenin (5-MeO-DMT) · GH001
Small molecule
Evidence outlook · lead readout
NCT05800860 · Treatment-resistant Depression
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05800860: The study randomly assigned 81 participants and used quadruple blinding with a placebo comparator. Its primary endpoint was the change in MADRS depression scores from baseline to Day 7, but results are not posted, so it is not possible to determine whether the primary endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.